製藥·生物科技的前臨床階段的聯盟條件與契約(2020年～2025年)

本報告探討了製藥和生物技術產業，提供了全面的數據驅動分析，闡述了企業簽訂臨床前合作協議的方式和原因，以及影響這些合作的關鍵財務和策略因素。

目錄

摘要整理

第1章 簡介

第2章 公司為何在臨床前化合物研發上進行合作

• 簡介
• 臨床前合作的作用
  • 臨床前許可
  • 臨床前許可
• 發現、臨床前和臨床協議之間的區別
• 建立臨床前合作的原因
  • 授權人建立臨床前協議的原因
  • 被授權人建立臨床前協議的原因
• 臨床前合作的未來

第3章 前臨床階段的契約策略與結構

• 簡介
• 企業哪個階段協作
  • 早期製藥/生技合作
  • 後期製藥/生技合作
• 早期與後期合作：風險與成本比較
• 公司在臨床前合作上花費多少？
• 純/多組分合作協議
• 純許可協議結構
  • 純臨床前許可協議範例
  • a. 個案研究 9
  • b. 個案研究 10
• 多組分臨床前合作協議
  • 多組分臨床前條款範例
  • a. 個案研究 11
  • b.個案研究 12

第4章 前臨床階段的聯盟的付款策略

• 簡介
• 前臨床階段的付款策略
• 付款方式
  • 總金額
  • 預付款
  • 貸款
  • 可轉換貸款
  • 公平性
  • 研發資金
  • 許可費
  • 里程碑付款
  • 特許權使用費率
  • 英鎊
  • 可選付款

第5章 前臨床階段的契約趨勢

• 簡介
• 年度的前臨床階段的聯盟
  • 前臨床契約的屬性
• 依協議建立的臨床前合作類型
• 按疾病類型劃分的臨床前合作夥伴關係
• 按技術類型劃分的臨床前合作夥伴關係
• 最活躍的臨床前合作關係（2020 年至今）

第6章 前臨床階段的聯盟的付款條件

• 簡介
• 前臨床階段的付款條件相關指南
  • 預付款
  • 階段性付款
  • 授權使用費
• 前臨床階段的付款條件 - 契約資料的分析
  • 公開資料
  • 調查資料
• 付款條件分析
  • 前臨床階段的標題金額
  • 前臨床階段的契約的預付款
  • 前臨床階段的契約的階段性付款
  • 前臨床階段的權利金費率

第7章 前主要臨床階段的契約

• 簡介
• 前臨床階段前幾名契約(金額)

第8章 最活躍的前臨床階段的契約企業前25名公司

• 簡介
• 最活躍的前臨床階段的契約企業前25名公司

第9章 前臨床階段的聯盟契約名錄

• 簡介
• 前臨床階段的契約(2020年～)

第10章 前臨床階段的契約:各開發階段

• 簡介
• 契約:前各臨床階段

附錄

Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025)

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025 report provides a comprehensive, data-driven analysis of how and why companies enter preclinical-stage partnering agreements, as well as the key financial and strategic terms shaping these partnerships. This essential industry resource delivers unparalleled insights into the structure, negotiation dynamics, and financial considerations that define early-stage pharmaceutical and biotech collaborations.

At the preclinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's drug candidate or technology. These agreements are often multifaceted, beginning with collaborative R&D efforts and potentially culminating in commercialization agreements.

This report provides detailed intelligence on the latest preclinical-stage agreements in the healthcare sector, helping companies evaluate market trends, optimize negotiation strategies, and benchmark deal structures.

A Must-Have Resource for Biotech and Pharma Dealmakers

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.

With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:

• Benchmarking deal structures and financial terms
• Optimizing negotiation strategies
• Assessing potential partners' flexibility
• Identifying trends in preclinical-stage partnerships
• Why This Report is Essential for Dealmakers
• Understanding a potential partner's negotiation flexibility and deal structures is critical when entering preclinical-stage partnerships. While headline financial figures (e.g., upfront payments, milestones, royalties) are important, contract documents reveal the precise triggers and conditions for these payments-details that are often missing from press releases and traditional deal databases.
• This report provides a comprehensive listing of over 1,670 preclinical-stage deals announced since 2020, including financial terms where available. Additionally, it includes direct links to online deal records, along with publicly available contract documents submitted to the SEC.
• By analyzing these agreements, companies can gain critical insights to refine deal strategies, assess partner flexibility, and structure competitive agreements.
• Comprehensive Analysis of Preclinical-Stage Partnering Trends

The first chapters of this report offer a detailed orientation to preclinical-stage deal-making, including:

Chapter 1 - Introduction to the report

Chapter 2 - Why companies engage in preclinical-stage partnerships

Chapter 3 - Strategic approaches and deal structures, with case studies

Chapter 4 - Payment strategies, including upfronts, milestones, and royalties

Chapter 5 - Analysis of preclinical-stage deal activity (2020-2025), categorized by year, stage of development, therapeutic area, technology type, and key dealmakers

Chapter 6 - In-depth financial analysis of headline values, upfront payments, milestone triggers, and royalty rates

Chapter 7 - A review of the leading preclinical-stage deals by headline value

Chapter 8 - Profiles of the top 25 most active preclinical-stage dealmakers

Chapter 9 - A database of preclinical-stage partnering agreements, including contract documents where available

Chapter 10 - A comprehensive directory of all preclinical-stage deals announced since 2020

• Key Benefits of the Report

This must-have industry resource provides exclusive insights to help companies assess, structure, and negotiate their own preclinical-stage partnerships. Key benefits include:

• Time-Saving Market Intelligence - Eliminate the need for manual research with ready-to-use insights on industry trends and deal structures.
• Unmatched Financial Data Access - Gain exclusive insight into headline values, upfront payments, milestone structures, and royalty terms to optimize negotiations.
• Comprehensive Deal Database - Access over 1,670 preclinical-stage agreements, including contract documents where available.
• Deep-Dive into Industry Leaders - Analyze actual preclinical-stage deals entered into by the top 25 global pharma and biotech companies, alongside emerging players.
• Strategic Case Studies & Deal Analysis - Examine real-world deal structures and negotiation strategies to enhance your own business development approach.
• High-Value Deal Identification - Pinpoint the most lucrative preclinical-stage deals signed since 2020, gaining insight into premium industry transactions.
• Profile the Most Active Dealmakers - Identify key players driving preclinical-stage collaborations, ensuring you engage with the right partners.
• Full Deal Listings & Categorization - Navigate a complete A-Z listing of preclinical-stage agreements, categorized by company, development phase, deal type, therapeutic area, and technology focus.
• Negotiate with Confidence - Understand the key terms and conditions agreed upon in previous deals, helping you structure optimal agreements.
• Robust Due Diligence Support - Conduct data-backed assessments to determine the viability and competitiveness of your proposed deal terms.
• Scope of the Report

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report provides:

• Trends in preclinical-stage dealmaking in the biopharma industry since 2020
• Detailed deal structures, including upfront, milestone, and royalty terms
• Case studies of real-life preclinical-stage agreements
• Access to over 1,670 preclinical-stage deals, with contract records where available
• Profiles of the most active preclinical-stage dealmakers since 2020
• Analysis of the highest-value preclinical-stage deals

Each deal record is indexed by:

• Company (A-Z)
• Headline Value
• Deal Type
• Specific Therapy Focus
• Technology Focus
• Critical Questions Answered

By analyzing actual contract agreements where available, this report provides definitive answers to critical questions such as:

• What specific rights are granted in each agreement?
• What exclusivity terms apply?
• How is the deal structured financially? (Upfronts, milestones, royalties)
• Who controls development, manufacturing, and commercialization?
• How are intellectual property rights handled?
• What are the termination conditions for the agreement?
• What dispute resolution mechanisms are in place?
• How are confidentiality and publication rights managed?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner preclinical stage compounds?

• 2.1. Introduction
• 2.2. The role of preclinical stage partnering
  • 2.2.1. In-licensing at preclinical stage
  • 2.2.2. Out-licensing at preclinical stage
• 2.3. Difference between discovery, preclinical and clinical stage deals
• 2.4. Reasons for entering into preclinical stage partnering deals
  • 2.4.1. Licensors reasons for entering preclinical stage deals
  • 2.4.2. Licensees reasons for entering preclinical stage deals
• 2.5. The future of preclinical stage partnering deals

Chapter 3 - Preclinical stage deal strategies and structure

• 3.1. Introduction
• 3.2. At what stage do companies partner?
  • 3.2.1. Partnering early in pharmaceutical / biotech
  • 3.2.1.1. Discovery and preclinical stage partnering case studies
  • 3.2.1.1.a. Case study 1
  • 3.2.1.1.b. Case study 2
  • 3.2.1.1.c. Case study 3
  • 3.2.1.1.d. Case study 4
  • 3.2.2. Partnering later in pharmaceutical/biotech
  • 3.2.2.1. Clinical stage partnering case studies
  • 3.2.2.1.a. Case study 5
  • 3.2.2.1.b. Case study 6
  • 3.2.2.1.c. Case study 7
  • 3.2.2.1.d. Case study 8
• 3.3. Early and later stage partnering - a risk/cost comparison
• 3.4. What do companies spend on preclinical stage partnering?
• 3.5. Pure versus multi-component partnering deals
• 3.6. Pure licensing agreement structure
  • 3.6.1. Example pure preclinical stage licensing agreements
  • 3.6.1.a. Case study 9
  • 3.6.1.b. Case study 10
• 3.7. Multicomponent preclinical stage partnering agreements
  • 3.7.1. Example multicomponent preclinical stage clauses
  • 3.7.1.a. Case study 11
  • 3.7.1.b. Case study 12

Chapter 4 - Preclinical stage partnering payment strategies

• 4.1. Introduction
• 4.2. Preclinical stage payment strategies
• 4.3. Payment options
  • 4.3.1. Headline values
  • 4.3.2. Upfront payments
  • 4.3.2.1. Conditionality of upfront payments
  • 4.3.3. Loans
  • 4.3.4. Convertible loans
  • 4.3.5. Equity
  • 4.3.6. R&D funding
  • 4.3.7. Licensing fees
  • 4.3.8. Milestone payments
  • 4.3.9. Royalty payments
  • 4.3.9.1. Issues affecting royalty rates
  • 4.3.9.2. Royalties on combination products
  • 4.3.9.2.a. Case study 13
  • 4.3.9.3. Guaranteed minimum/maximum annual payments
  • 4.3.9.4. Royalty stacking
  • 4.3.9.5. Royalties and supply/purchase contracts
  • 4.3.10. Quids
  • 4.3.11. Option payments

Chapter 5 - Trends in preclinical stage deal making

• 5.1. Introduction
• 5.2. Preclinical stage partnering over the year
  • 5.2.1. Attributes of preclinical deals
• 5.3. Preclinical stage partnering by deal type
• 5.4. Preclinical stage partnering by disease type
• 5.5. Partnering by preclinical stage technology type
• 5.6. Preclinical stage partnering by most active company, 2020 - 2025

Chapter 6 - Payment terms for preclinical stage partnering

• 6.1. Introduction
• 6.2. Guidelines for preclinical stage payment terms
  • 6.2.1. Upfront payments
  • 6.2.2. Milestone payments
  • 6.2.3. Royalty payments
• 6.3. Preclinical stage payment terms - deal data analysis
  • 6.3.1. Public data
  • 6.3.2. Survey data
• 6.4. Payment terms analysis
  • 6.4.1. Preclinical stage headline values
  • 6.4.2. Preclinical stage deal upfront payments
  • 6.4.3. Preclinical stage deal milestone payments
  • 6.4.4. Preclinical stage royalty rates

Chapter 7 - Leading preclinical stage deals

• 7.1. Introduction
• 7.2. Top preclinical stage deals by value

Chapter 8 - Top 25 most active preclinical stage dealmakers

• 8.1. Introduction
• 8.2. Top 25 most active preclinical stage dealmakers

Chapter 9 - Preclinical stage partnering contracts directory

• 9.1. Introduction
• 9.2. Preclinical stage deals with contracts 2020 - 2025

Chapter 10 - Preclinical stage deal making by development stage

• 10.1. Introduction
• 10.2. Deals by preclinical stage

Appendices

• Appendix 1 - Preclinical stage dealmaking by companies A-Z
• Appendix 2 - Preclinical stage dealmaking by industry sector
• Appendix 3 - Preclinical stage dealmaking by stage of development
• Appendix 4 - Preclinical stage dealmaking by therapy area
• Appendix 5 - Preclinical stage dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent titles from Current Partnering

Table of figures

• Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
• Figure 2: Components of the pure licensing deal structure
• Figure 3: Payment options for preclinical stage partnering deals
• Figure 4: Issues affecting royalty rates
• Figure 5: Preclinical stage partnering frequency 2020 - 2025
• Figure 6: Preclinical stage partnering by deal type since 2020
• Figure 7: Preclinical stage partnering by disease type since 2020
• Figure 8: Preclinical stage partnering by technology type since 2020
• Figure 9: Top 25 most active preclinical stage dealmakers, 2020 - 2025
• Figure 10: Review of upfront payments for preclinical stage deals
• Figure 11: Review of milestone payments for preclinical stage deals
• Figure 12: Review of royalty payments for preclinical stage deals
• Figure 13: Preclinical stage deals with a headline value
• Figure 14: Preclinical stage deals with an upfront value
• Figure 15: Preclinical stage deals with a milestone value
• Figure 16: Preclinical stage deals with a royalty rate value
• Figure 17: Top preclinical stage deals by value since 2020
• Figure 18: Most active preclinical stage dealmakers 2020 - 2025